CLINICAL TRIALS PROFILE FOR VARIBAR HONEY

All Clinical Trials for VARIBAR HONEY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01525927 ↗	Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity	Terminated	Northwell Health	Phase 2	2010-08-01	This study looks at the use of three cycles of chemotherapy given prior to radiation therapy in patients with cancer of the oral cavity and evidence of prior exposure to Human Papilloma Virus (HPV). Patients with cancer of the oral cavity who have evidence of exposure to HPV have a better prognosis than those who do not have such evidence of exposure to HPV. The main hypothesis of this study is that using three cycles of chemotherapy prior to embarking on radiation therapy will allow the use of reduced doses of radiation therapy and, therefore, less radiation induced side-effects. The primary objective is to determine the activity of this pre-radiation chemotherapy strategy along with reduced dose levels of radiation with or without chemotherapy during the radiation phase. The effectiveness of the strategy will be assessed at three months following the completion of the radiation therapy phase and also at two years following completion of the radiation therapy.

Clinical Trial Conditions for VARIBAR HONEY

Condition Name

Condition Name for VARIBAR HONEY
Intervention	Trials
Oropharyngeal Neoplasms	1

Condition MeSH

Condition MeSH for VARIBAR HONEY
Intervention	Trials
Oropharyngeal Neoplasms	1
Neoplasms	1

Clinical Trial Locations for VARIBAR HONEY

Trials by Country

Trials by Country for VARIBAR HONEY
Location	Trials
United States	1

Trials by US State

Trials by US State for VARIBAR HONEY
Location	Trials
New York	1

Clinical Trial Progress for VARIBAR HONEY

Clinical Trial Phase

Clinical Trial Phase for VARIBAR HONEY
Clinical Trial Phase	Trials
Phase 2	1

Clinical Trial Status

Clinical Trial Status for VARIBAR HONEY
Clinical Trial Phase	Trials
Terminated	1

Clinical Trial Sponsors for VARIBAR HONEY

Sponsor Name

Sponsor Name for VARIBAR HONEY
Sponsor	Trials
Northwell Health	1

Sponsor Type

Sponsor Type for VARIBAR HONEY
Sponsor	Trials
Other	1

Last updated: June 8, 2026

Varibar Honey (lactitol oral) clinical trials update, market analysis, and projection

Executive summary: Varibar Honey is a branded oral barium contrast product used with radiology procedures. No reliable, current clinical-trials dataset or recent FDA/NDA commercialization milestones are available in the information provided here, so a complete, accurate clinical-trials update, market sizing, and forecast cannot be produced.

What clinical trials have been conducted for Varibar Honey (lactitol oral)?

Answer: No complete, verifiable clinical-trials update can be generated from the information provided.

Which endpoints and study designs are associated with Varibar Honey?

Answer: Not available from provided inputs.

Is Varibar Honey studied for pediatric use, GI transit, or dysphagia screening?

Answer: Not available from provided inputs.

Are there trials comparing Varibar Honey vs. alternative barium contrast agents?

Answer: Not available from provided inputs.

---

What is the current FDA regulatory status of Varibar Honey?

Answer: Not available from the information provided.

Is Varibar Honey listed in the Orange Book?

Answer: Not available from the information provided.

What is the approved route, dosage form, and labeling scope?

Answer: Not available from the information provided.

---

How many patents protect Varibar Honey and how strong is the IP estate?

Answer: Not available from the information provided.

What patents cover manufacturing, formulation, and method-of-use?

Answer: Not available from the information provided.

Are there Paragraph IV generic challenges for Varibar Honey?

Answer: Not available from the information provided.

What patent litigation has affected availability or pricing?

Answer: Not available from the information provided.

---

Who sells Varibar Honey and what is the competitive landscape?

Answer: Not available from the information provided.

Which companies compete with Varibar Honey in radiology contrast screening?

Answer: Not available from the information provided.

How does Varibar Honey compare with other oral contrast agents (taste, dosing, administration)?

Answer: Not available from the information provided.

---

What is the market size for Varibar Honey and how fast is it growing?

Answer: Not available from the information provided.

What segments drive demand (hospital vs. ambulatory; adult vs. pediatric; GI vs. swallow studies)?

Answer: Not available from the information provided.

What is the pricing and reimbursement profile for Varibar Honey?

Answer: Not available from the information provided.

---

When does Varibar Honey lose exclusivity or face generic entry risk?

Answer: Not available from the information provided.

What regulatory exclusivities apply (if any)?

Answer: Not available from the information provided.

What are the key risks to supply continuity (manufacturing, recalls, sourcing)?

Answer: Not available from the information provided.

---

How should investors and commercial teams project Varibar Honey revenue over the next 3–7 years?

Answer: Not available from the information provided.

Base case vs. downside vs. upside scenario drivers

Answer: Not available from the information provided.

Adoption curve assumptions (site penetration, conversion from other contrast products)

Answer: Not available from the information provided.

---

Key Takeaways

No complete and accurate clinical-trials update, regulatory positioning, patent/IP landscape, or market projections for Varibar Honey can be produced based on the information provided.

FAQs

1. What evidence supports Varibar Honey use in pediatric radiology and swallow studies?
2. Is Varibar Honey interchangeable with other oral barium contrast products by labeling?
3. How does FDA labeling for Varibar Honey constrain off-label substitution risk?
4. What manufacturing or supply constraints affect availability of oral contrast agents like Varibar Honey?
5. What competitive pressure arises when generics or private-label contrast equivalents enter the same billing channels?

References

(No sources cited because no verifiable clinical, regulatory, patent, or market data was provided in the input.)